Trial reportEuropean journal of nuclear medicine and molecular imaging2026
Predictive and prognostic role of volumetric analyses and lymphoma dissemination in pediatric HL: a prospective, multicenter, cohort study.
Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.British journal of haematology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the present trial is to investigate the predictive and prognostic role of PET volumetric parameters and maximal dissemination (Dmax) in pediatric Hodgkin lymphoma (HL). MATERIALS AND
methodsThis is a prospective, multicenter study conducted in 35 AIEOP centers. Between March 2018 and December 2020, pediatric HL patients undergoing the same therapeutic trial have been enrolled. Patients underwent PET at baseline (PET0), for early (ERA), and late response assessment (LRA). The parameters analyzed were SUVmax, SUVmean, Dmax, TMTV (total metabolic tumor volume), TLG (total lesion glycolysis), and their (Δ) variations at different timing. Clinical and imaging parameters have been correlated to response, classified into adequate (AR) and inadequate (IR), based on protocol definition, and the event-free survival (EFS).
resultsOverall, 300 patients were enrolled: 144 were male (48%), 167 stage I-II and 133 stage III-IV, 114 presented with bulky masses (> 200 ml), whereas 167 patients showed B-symptoms. All PET0 parameters resulted significantly correlated to ERA PET. With respect to the outcome, volumetric parameters and Dmax resulted prognostic at PET0, while semi-quantitative parameters and Dmax resulted prognostic at ERA PET. At multivariate analyses, an independent prognostic role was proven for stage (p = 0.0026), bulky volume (p < 0.0001), and Dmax (p = 0.0388) at PET0. Whereas, Dmax (p = 0.0025) and ΔSUVmax (p = 0.0297) resulted independent prognostic factors at ERA. By combining factors, we found a significant difference for patients with no risk factors at PET0 compared to patients with three risk factors (HR 17.701; p < 0.0001). At ERA PET, the poorest outcome was reached in case of bi-factorial risks, with a mean EFS of 56.4 months (HR 23.489; p < 0.0001).
conclusionsTo our knowledge, this is the first large, prospective, multicenter study of its type in pediatric patients. Our findings demonstrate the role of PET volumetric parameters in pediatric HL. Moreover, as first evidence in children, Dmax showed a proper predictive and prognostic role in HL. By combining these factors, we could stratify patients into risk-groups based on the outcomes.
Indexed as
Identifiers
40956409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.